-       Report 
   - November 2025
    -  289 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - August 2025
    -  150 Pages 
    Global
   
   From       €3460EUR$3,850USD£3,035GBP 
                  -       Report 
   - April 2025
    -  150 Pages 
    Global
   
   From       €3460EUR$3,850USD£3,035GBP 
      €4359EUR$4,850USD£3,823GBP 
                   -       Report 
   - March 2025
    -  150 Pages 
    Global
   
   From       €3460EUR$3,850USD£3,035GBP 
      €4359EUR$4,850USD£3,823GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2426EUR$2,699USD£2,128GBP 
                -       Report 
   - June 2025
    -  200 Pages 
    Global
   
   From       €2507EUR$2,789USD£2,198GBP 
                -       Drug Pipelines 
   - June 2025
    -  200 Pages 
    Global
   
   From       €2507EUR$2,789USD£2,198GBP 
                -       Report 
   - September 2025
    -  30 Pages 
    United States
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - February 2023
    -  317 Pages 
    Global
   
   From       €4494EUR$5,000USD£3,941GBP 
                -       Report 
   - April 2023
    -  115 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - May 2024
    -  138 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                -       Report 
   - May 2024
    -  182 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - November 2023
    -  182 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                -       Report 
   - February 2022
    -  39 Pages 
    Global
   
   From       €1798EUR$2,000USD£1,577GBP 
                -       Report 
   - August 2024
    -  178 Pages 
    Global
   
   From       €2247EUR$2,500USD£1,971GBP 
                -       Report 
   - April 2024
    -  140 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - May 2023
    -  160 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                  -       Report 
   - October 2025
    -  27 Pages 
    Hong Kong, China
   
   From       €995EUR$1,186USD£903GBP 
             
         The Decongestant market is a subset of the Cough and Cold Drugs market, which includes medications used to treat symptoms of the common cold, such as nasal congestion, sinus pressure, and chest congestion. Decongestants are typically available in both over-the-counter (OTC) and prescription forms, and are often used in combination with other medications to treat cold and flu symptoms. Decongestants work by narrowing the blood vessels in the nasal passages, reducing inflammation and allowing for    easier breathing.
Common OTC decongestants include pseudoephedrine, phenylephrine, and oxymetazoline. Prescription decongestants include ephedrine, phenylephrine, and phenylpropanolamine. Decongestants are also available in combination with other medications, such as antihistamines, expectorants, and cough suppressants.
Some companies in the Decongestant market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Merck, and Sanofi. Show Less   Read more